|
|
Volumn 28, Issue 11, 2011, Pages 1281-
|
|
Persistent lipid abnormalities in diabetes; are we approaching the treatment optimally?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EZETIMIBE;
FIBRIC ACID DERIVATIVE;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
NICOTINIC ACID;
SIMVASTATIN;
TRIACYLGLYCEROL;
CARDIOVASCULAR DISEASE;
CHOLESTEROL BLOOD LEVEL;
CLINICAL TRIAL (TOPIC);
CROSS-SECTIONAL STUDY;
DIABETES MELLITUS;
DYSLIPIDEMIA;
EDITORIAL;
HUMAN;
OUTPATIENT;
PHYSICIAN ATTITUDE;
TRIACYLGLYCEROL BLOOD LEVEL;
ANTICHOLESTEREMIC AGENTS;
CARDIOVASCULAR DISEASES;
DIABETES MELLITUS, TYPE 2;
DIABETIC ANGIOPATHIES;
DYSLIPIDEMIAS;
FEMALE;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
MALE;
METABOLIC SYNDROME X;
|
|
EID: 80054683486
PISSN: 07423071
EISSN: 14645491
Source Type: Journal
DOI: 10.1111/j.1464-5491.2011.03452.x Document Type: Editorial |
|
Times cited : (1)
|
|
References (0)
|
